Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicet BioACET +0.06%34 Debt-to-Equity is 0.11 as of Jun. 2026, which is 22% above its 10-year median of 0.09. GuruFocus rates ACET with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 967 Biotechnology companies, Adicet Bio ranks better than 56.77% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Adicet Bio's Debt-to-Equity or its related term are showing as below:
ACET'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.09 Max: 0.2
Current: 0.11
During the past 8 years, the highest Debt-to-Equity Ratio of Adicet Bio was 0.20. The lowest was 0.07. And the median was 0.09.
ACET's Debt-to-Equity is ranked better than 56.77% of 967
companies
in the Biotechnology industry
Industry Median: 0.16
vs ACET: 0.11
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Adicet Bio Debt-to-Equity Related Terms
Adicet Bio Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Adicet Bio's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACET vs ATRA, PYPD, GANX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Adicet Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Adicet Bio's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (ACET) has a Debt-to-Equity of 0.11 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Adicet Bio and its competitors. This is 22% above median its historical median of 0.09. Over the past decade, Adicet Bio's Debt-to-Equity has ranged from 0.07 to 0.20. According to the industry distribution chart, Adicet Bio ranks #418 out of 967 companies in the Biotechnology industry, placing it in the top 43.2%.
Is Adicet Bio's Debt-to-Equity too high?
Adicet Bio's current Debt-to-Equity of 0.11 is 22% above median its 10-year median of 0.09. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 0.20. The Biotechnology industry median Debt-to-Equity is 0.16. Adicet Bio's value of 0.11 is 31.3% below this industry median. Based on the distribution chart, Adicet Bio ranks #418 out of 967 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Adicet Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Debt-to-Equity compare to ATRA and PYPD?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #418 out of 967 companies for Debt-to-Equity. This puts Adicet Bio in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Adicet Bio's value of 0.11 is 31.3% below this benchmark. Historically, Adicet Bio's own Debt-to-Equity has ranged from 0.07 to 0.20 over the past decade. While the company's 10-year median is 0.09 vs. the industry median of 0.16, Adicet Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adicet Bio's current Debt-to-Equity of 0.11 is 31.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Adicet Bio and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adicet Bio's current Debt-to-Equity is 0.11, which is 22% above median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (ACET) has a current Debt-to-Equity of 0.11. The current Debt-to-Equity is 0.11, which is 22% above median its 10-year median of 0.09 and 31.3% below the Biotechnology industry median of 0.16. Adicet Bio's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Adicet Bio (ACET), the current Debt-to-Equity is 0.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
34GF Score
Get the complete analysis for ACET
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACET has been successfully added to your 
